Immunodiagnostics

History

2024: Global Immunodiagnosis Market Growth to $22.2 Billion

In 2024, costs in the global immunodiagnosis market reached $22.2 billion. More than a third of this amount fell on the North American region. Industry trends are addressed in a Fortune Business Insights study, the results of which were released on April 9, 2025.

Immunodiagnostics is a technique in which the main way to detect infectious diseases, malignant tumors, drug use, diabetes mellitus, as well as specific proteins, drugs and allergens is to analyze antibodies to identify certain pathogens. Modern immunological research methods are used in allergology, hematology, in the study of infectious and oncological diseases, hormonal disorders, etc. The technology allows diagnosing primary (congenital) and secondary (arising at different periods of life under the influence of various causes) immunodeficiency conditions, autoimmune and allergic diseases, lymphomas, leukemias, etc. In particular, mass immunodiagnosis is used - a method of preventive detection of tuberculosis infection in children.

The authors of the study note that the global immunodiagnosis market is showing steady positive dynamics, which is explained, in particular, by the growing prevalence of infectious diseases such as hepatitis, HIV, respiratory infections, etc. The demand for immunodiagnostics tools is further increasing due to the aging population: with the growing number of older people who are more susceptible to certain diseases, health care providers are looking for effective systems to detect infectious ailments. Technological advances play an important role in the development of the industry: large companies invest heavily in research and development related to advanced methods of immunodiagnosis. In addition, there has been an increase in health care spending in certain regions.

However, there are also certain deterrents. Current methods of immunodiagnosis are quite expensive, and therefore access to them in developing countries and low-income regions can be difficult.

In terms of the application of immunodiagnosis methods, oncology and endocrinology, hepatitis and retroviruses, cardiac markers and infectious diseases are distinguished. In 2024, the first of these areas provided the largest share - approximately 28.2%. From the point of view of product types, the segment of reagents and consumables is showing the most significant growth due to the increase in the number of diagnostic procedures. Geographically, North America leads, which in 2024 accounted for about 37% of the global cost, or $8.24 billion. The dominant position in the global market is occupied by developed countries, but their further growth rate is expected to be lower compared to developing regions. The key players in the industry are:

• Abbott;
• Hoffmann-La Roche AG ( Roche Diagnostics );
• DiaSorin;
• Danaher Corporation;
• [[Qiagen];
• bioMérieux;
• Thermo Fisher Scientific;
• Quest Diagnostics.

In 2025, the cost of immunodiagnosis worldwide is expected to be $23.52 billion. Fortune Business Insights analysts believe that in the future, the CAGR in the market under consideration will be at the level of 7%. As a result, costs globally could rise to $38.06 billion by 2032.^[1]

Notes